Interestingly, several clinical trials have shown that the combination of local tumor treatment with T-VEC and systemic administration of ICIs, such as anti-CTLA-4 and anti-PD-1 mAbs, results in increased antitumor efficacies [108,109]. This evidence concerns the gene CTLA4 and neoplasm.